Lidocaine hydrochloride is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide.
The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of Lidocaine hydrochloride. Approximately 90% of Lidocaine hydrochloride administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline.

Function:

1. Lidocaine, xylocaine, or lignocaine is a common local anesthetic and class-1b antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning, and pain from skin inflammations, injected as a dental anesthetic, or as a local anesthetic for minor surgery.
 
2.It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic healthcare system.
 
3. Lidocaine is the most important class-1b antiarrhythmic drug; it is used intravenously for the treatment of ventricular arrhythmias (for acute myocardial infarction, digoxine poisoning, cardioversion, or cardiac catheterization) if amiodarone is not available or contraindicated.
 
4. Lidocaine should be given for this indication after defibrillation, CPR, and vasopressors have been initiated. A routine prophylactic administration is no longer recommended for acute cardiac infarction; the overall benefit of this measure is not convincing.

Lidocaine Hcl Description:

1.Lidocaine hcl is a local anesthetic and antiarrhythmic drug. It is clinically used for infiltration anesthesia, epidural anesthesia, surface anesthesia (including in the thoracoscopy or abdominal surgery for mucosal anesthesia) and nerve conduction block.

2.Lidocaine hcl is an amide local anesthetic. With the dose increased, the role or toxicity increased, there is an anti-convulsive effect with sub-poisoning plasma concentration; Blood concentration of more than 5μg • ml-1 can occur convulsions.

3.Lidocaine hcl in low doses can promote outflow of K+ in cardiomyocytes, reduce myocardial autonomy, and has antiarrhythmic effects.  Increased plasma concentration may cause slowing of heart conduction, atrioventricular block, inhibition of myocardial contractility and decreased cardiac output.

NMN CAS: 1094-61-7
Nr CAS: 1341-23-7
Procaine CAS :59-46-1
Benzocaine CAS :94-09-7
Lidocaine CAS:137-58-6
Acetaminophen CAS :103-90-2
Boric acid CAS : 11113-50-1
Tetracain hcl CAS :136-47-0
Valerophenoone CAS :1009-14-9
2-Bromo-1-phenyl-1-pentanone CAS:49851-31-2
2-Bromo-4'-Methylpropiophenone CAS:1451-82-7
Tetramisole hcl CAS:5086-74-8 ,
Hydrochloride CAS:593-51-1
hcl CAS:73-78-9
Procaine hcl CAS:51-05-8
Benzocaine CAS:94-09-7
CAS:137-58-6
Ethephon CAS:16672-87-0
New BMK CAS:5413-05-8
BDO CAS:110-63-4
(2-Bromoethyl)benzene CAS:103-63-9
Clotrimazole CAS:23593-75-1
Tretinoin CAS:302-79-4 ETC.
4'-Methylpropiophenone CAS 5337-93-9
Benzene CAS 103-63-9
DMAA CAS 13803-74-2